- Home
- BEAM vs DHC Comparison
BEAM vs DHC Comparison
Compare BEAM & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAM | DHC |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2019 | 1998 |
Fundamental Metrics
Financial Performance| Metric | BEAM | DHC |
|---|---|---|
| Price | $28.45 | $8.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $50.75 | $8.00 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.53% |
| EPS Growth | ★ 82.31 | 23.23 |
| EPS | N/A | ★ N/A |
| Revenue | $24,000.00 | ★ $1,074,819,000.00 |
| Revenue This Year | N/A | $3.13 |
| Revenue Next Year | $33.77 | $7.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 33.33 | 1.59 |
| 52 Week Low | $16.03 | $3.64 |
| 52 Week High | $38.26 | $9.66 |
Technical Indicators
Market Signals| Indicator | BEAM | DHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 36.07 |
| Support Level | $28.03 | $6.92 |
| Resistance Level | $28.96 | $9.66 |
| Average True Range (ATR) | 1.28 | 0.33 |
| MACD | 0.45 | -0.05 |
| Stochastic Oscillator | 57.10 | 9.41 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.